<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2013-03-03" updated="2019-12-02">
  <drugbank-id primary="true">DB08862</drugbank-id>
  <name>Cholecystokinin</name>
  <description>Cholecystokinin ( also known as _CCK or CCK-PZ_) is a peptide hormone of the gastrointestinal system which is responsible for stimulating the digestion of fat and protein. Cholecystokinin, previously called _pancreozymin_, is synthesized and secreted by enteroendocrine cells in the duodenum (the first portion of the small intestine) and leads to the release of bile and digestive enzymes. CCK also acts as an appetite suppressant and has been studied for weight management regimens [L1637]. &#13;
&#13;
Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.&#13;
&#13;
&#13;
&#13;
Cholecystokinin is one of the first gastrointestinal hormones discovered, identified more than 90 years ago due to its ability to stimulate gallbladder contraction in 1928. Soon after, it was recognized to be identical to the factor responsible for stimulating pancreatic exocrine secretion in 1943 [L1636]. This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system. In addition to its roles in promoting smooth muscle cell contraction/exocrine cell secretion, CCK promotes cell growth, energy production, gene expression and protein synthesis, processes that have profound for drug development [L1636].  This drug has also been investigated for possible antipsychotic properties, owing to its effect on CCK receptors in the brain [L1638].&#13;
&#13;
Recent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity during opioid withdrawal [A32101].</description>
  <cas-number>9011-97-6</cas-number>
  <unii>00XI8W60QF</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32101</ref-id>
        <pubmed-id>15894374</pubmed-id>
        <citation>Romanelli L, Morrone LA, Amico MC, Palmery M, Tucci P, Valeri P: Inhibitory control of the acute mu-withdrawal response by indirectly activated adenosine A1 and kappa-opioid systems in the Guinea-pig ileum; reversal by cholecystokinin. Neurotoxicology. 2005 Oct;26(5):829-39. doi: 10.1016/j.neuro.2005.02.001.</citation>
      </article>
      <article>
        <ref-id>A32102</ref-id>
        <pubmed-id>15533776</pubmed-id>
        <citation>Rehfeld JF: Clinical endocrinology and metabolism. Cholecystokinin. Best Pract Res Clin Endocrinol Metab. 2004 Dec;18(4):569-86. doi: 10.1016/j.beem.2004.07.002.</citation>
      </article>
      <article>
        <ref-id>A32103</ref-id>
        <pubmed-id>2991034</pubmed-id>
        <citation>Williams JA: Mechanism of action of cholecystokinin: a not atypical brain-gut peptide. Nihon Naibunpi Gakkai Zasshi. 1985 May 20;61(5):533-40.</citation>
      </article>
      <article>
        <ref-id>A32104</ref-id>
        <pubmed-id>8253350</pubmed-id>
        <citation>Hoffmann P, Eberlein GA, Reeve JR Jr, Bunte RH, Grandt D, Goebell H, Eysselein VE: Comparison of clearance and metabolism of infused cholecystokinins 8 and 58 in dogs. Gastroenterology. 1993 Dec;105(6):1732-6.</citation>
      </article>
      <article>
        <ref-id>A32106</ref-id>
        <pubmed-id>11713976</pubmed-id>
        <citation>Bradwejn J, Koszycki D: Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl. 2001;234:19-27.</citation>
      </article>
      <article>
        <ref-id>A32116</ref-id>
        <pubmed-id>11007512</pubmed-id>
        <citation>Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, Reubi JC, Krenning EP: Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000 Sep;27(9):1312-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1632</ref-id>
        <title>cholecystokinin</title>
        <url>http://www.vivo.colostate.edu/hbooks/pathphys/endocrine/gi/cck.html</url>
      </link>
      <link>
        <ref-id>L1633</ref-id>
        <title>Cholecystokinin metabolism in man and dogs</title>
        <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1344019/</url>
      </link>
      <link>
        <ref-id>L1634</ref-id>
        <title>Cholecystokinin</title>
        <url>https://www.drugs.com/mmx/cck.html</url>
      </link>
      <link>
        <ref-id>L1635</ref-id>
        <title>Cholecystokinin- a review</title>
        <url>https://www.sciencedirect.com/topics/chemistry/cholecystokinin</url>
      </link>
      <link>
        <ref-id>L1636</ref-id>
        <title>Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor</title>
        <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839260/</url>
      </link>
      <link>
        <ref-id>L1637</ref-id>
        <title>Cholecystokinin receptors in brain: Effects of obesity, drug treatment, and lesions Author links open overlay panel</title>
        <url>https://www.sciencedirect.com/science/article/abs/pii/0196978181900516</url>
      </link>
      <link>
        <ref-id>L1638</ref-id>
        <title>SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI</title>
        <url>https://link.springer.com/article/10.1007/s00213-002-1214-z</url>
      </link>
      <link>
        <ref-id>L1639</ref-id>
        <title>Physiology of CCK</title>
        <url>https://www.uptodate.com/contents/physiology-of-cholecystokinin</url>
      </link>
      <link>
        <ref-id>L1640</ref-id>
        <title>Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.</title>
        <url>https://www.ncbi.nlm.nih.gov/pubmed/12496267</url>
      </link>
      <link>
        <ref-id>L1641</ref-id>
        <title>Effect of Exogenous Cholecystokinin (CCK)-8 on Food Intake and Plasma CCK, Leptin, and Insulin Concentrations in Older and Young Adults: Evidence for Increased CCK Activity as a Cause of the Anorexia of Aging</title>
        <url>https://watermark.silverchair.com/jcem5830.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAaowggGmBgkqhkiG9w0BBwagggGXMIIBkwIBADCCAYwGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM8C4jETgsbOcKN1RJAgEQgIIBXby2TDMTqLoxgQ6ubmlN4HjHutX56ZK5YSit8uXY_SxCH-FeJHHRd96DO6Xelfs_AWHgOkwYiSjyYiuJ6R5G75IuAh7TqXiqfShWHfHPGcr6jbX8N95S0Q25p6CTV_9-3_c8L1bA6AmtrsINgJbKbocjEZYJz0Dw51NqiUsO8g8f8Junna_pmyfUuz8j4wEmV7mywP_MWfvtH85E-gZ1XvGsQ7CiBLVtSW2g_4VGxNQgySqQqOqwvwdBXWNGFaIdAEDcvTqNslGyKbBNDf9OG_vZdli5fQXImHAhuyg1MGK4DKqzXh1FLuaRnRpOILyQrw5Wdw9pmiH_t6LxvC4RDlG5gi_fhjlAbLBZSLFxxefkX9NV8s9_sjKTpGFpVRDLooh6_luWVvHcFmS8OyEbaj-Jy8E0d_n_JndMakMvJT1ijVQpi4RbOrA6zCGeAvlPoDhBVT5IfTTQ61uJSsQ</url>
      </link>
      <link>
        <ref-id>L1642</ref-id>
        <title>Comparison of Gallbladder Function Obtained with Regular CCK-8 and Pharmacy-Compounded CCK-8</title>
        <url>http://jnm.snmjournals.org/content/44/4/499.full</url>
      </link>
      <link>
        <ref-id>L1643</ref-id>
        <title>Bioactivity of synthetic human cholecystokinin (CCK)-33 in vitro and in vivo</title>
        <url>https://link.springer.com/article/10.1007%2FBF02779509</url>
      </link>
      <link>
        <ref-id>L1644</ref-id>
        <title>Cholecystokinin Octapeptide </title>
        <url>https://pubchem.ncbi.nlm.nih.gov/compound/16219094</url>
      </link>
      <link>
        <ref-id>L1645</ref-id>
        <title>Cholecystokinin Octapeptide, [125I]-, Bolton-Hunter Labeled, 10µCi</title>
        <url>http://www.perkinelmer.ca/en-ca/product/cholecystokinin-octapeptide-125i-bolt-nex203010uc</url>
      </link>
      <link>
        <ref-id>L1646</ref-id>
        <title>Alfa Aesar™ Cholecystokinin, CCK Octapeptide (26-33)</title>
        <url>https://www.fishersci.ca/shop/products/cholecystokinin-cck-octapeptide-26-33-2/p-5384644</url>
      </link>
      <link>
        <ref-id>L1647</ref-id>
        <title>Cholecystokinin-Pancreozymin Peptides Products</title>
        <url>http://www.biosyn.com/catalog-peptides/cholecystokinin-pancreozymin-peptides.aspx</url>
      </link>
      <link>
        <ref-id>L1648</ref-id>
        <title>CCK Octapeptide sulfated</title>
        <url>https://www.tocris.com/products/cck-octapeptide-sulfated_1166</url>
      </link>
      <link>
        <ref-id>L1649</ref-id>
        <title>Cholecystokinin Octapeptide</title>
        <url>https://www.perkinelmer.com/Content/MSDSDatabase/MSDS_NEX203010UC_AU_EN.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For use as a diagnostic aid for evaluation of gallbladder disorders.  It is also used in conjunction with secretin in pancreatic insufficiency [L1634].</indication>
  <pharmacodynamics>Cholecystokinin (CCK) plays an imperative role in facilitating digestion within the small intestine. The activation of the CCK1 receptor by CCK has demonstrated to be responsible for a wide variety of important physiologic functions, including the stimulation of gallbladder, contraction and exocrine pancreatic enzyme secretion, delay of gastric emptying, relaxation of the sphincter of Oddi, inhibition of gastric acid secretion, and induction of satiety [L1632, L1647]. Cholecystokinin is also produced by neurons in the enteric nervous system and is found to be widely distributed in the brain [L1632].  An interesting function of CCK is the role it plays in stimulating the CCK receptor and subsequently regulating food consumption, which may prove to be a highly useful treatment for obesity [L1639].   Exogenous administration CCK has been widely studied [L1641]. &#13;
&#13;
&#13;
Diseases resulting from excessive or deficient secretion of cholecystokinin are rare. Cholecystokinin deficiency has been described in humans as part of autoimmune polyglandular syndrome, characterized as a malabsorption syndrome clinically similar to pancreatic exocrine insufficiency. Additionally, there is increasing evidence that alterations in expression of cholecystokinin or its receptor within the brain may possibly play a role in the pathogenesis of various types of anxiety disorders and schizophrenia [L1632].&#13;
&#13;
Foodstuffs flowing into the small intestine are mostly made up of large macromolecules (proteins, polysaccharides, and triglyceride) that require digestion into small molecules (amino acids, monosaccharides, fatty acids) in order to be absorbed. Digestive enzymes from the pancreas and bile salts from the liver (which are stored in the gallbladder) are necessary for  digestion. Cholecystokinin is the primary stimulus for the release of pancreatic enzymes and bile secretion into the small intestine. Additionally, cholecystokinin,  induces contraction of the gallbladder muscle, resulting in the reduction of gallbladder size and evacuation of bile [L1634].</pharmacodynamics>
  <mechanism-of-action>Cholecystokinin (CCK) is a peptide hormone discovered in the small intestine. Together with secretin and gastrin, CCK constitutes the classical gut hormone triad. In addition to gallbladder contraction, CCK also regulates pancreatic enzyme secretion and growth, intestinal motility, satiety signaling and the inhibition of gastric acid secretion. CCK is, however, also a transmitter in central and intestinal neurons. Notably, CCK is the most ubiquitously found neuropeptide in the human brain. Owing to difficulties in developing accurate assays for the hormone, knowledge about CCK secretion in disease is limited. Available data indicate, however, that proCCK is expressed in certain malignant neuroendocrine tumors and sarcomas, whereas the secretion of CCK is affected in celiac disease and the eating disorder bulimia nervosa. Stimulation with exogenous CCK has proved this protein useful in diagnostic imaging of gallbladder and pancreatic diseases, as well as testing of medullary thyroid carcinomas [A32102, A32116, L1643].&#13;
&#13;
&#13;
Cholecystokinin, a natural polypeptide which is formed in the amine precursor uptake and decarboxylation (APUD) cells of the proximal mucosa of the small intestine, promotes contraction of the gallbladder muscle, resulting in the reduction of gallbladder size and the expression of bile [L1634]. Cholecystokinin stimulates secretion of pancreatic digestive enzymes and secretion from the glands of Brunner [L1634].&#13;
&#13;
CCK is composed of a five amino acid sequence at the carboxyl terminus that is identical to that of gastrin. The carboxyl terminus confers the biologic activity of CCK; as a result, gastrin has CCK-mimicking activity and CCK has gastrin-mimicking activity. The amino acid sequence similarity has made the creation of assays for CCK cumbersome, due to the fact that antibodies specific for the biologically active portion the molecule often cross-react with gastrin. This hormone circulates in the blood at concentrations 10 to 100 times greater than that of CCK [L1639].&#13;
&#13;
</mechanism-of-action>
  <toxicity>Ld 50 in rats : 2730 mg/kg (oral) [L1649].&#13;
&#13;
Cholecystokinin has been associated with increased anxiety and panic attacks [A32106].</toxicity>
  <metabolism/>
  <absorption/>
  <half-life>2.5 min [L1642]</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">CCK-PZ</synonym>
    <synonym language="english" coder="">Human CCK-33</synonym>
    <synonym language="english" coder="">Human cholecystokinin-33</synonym>
    <synonym language="english" coder="">Pancreozymin</synonym>
  </synonyms>
  <products>
    <product>
      <name>Cholecystokinin Inj 75unit/vial</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00873985</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-04</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Cholecystokinin Inj 75unit/vial</name>
      <ingredients>Cholecystokinin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Cholagogues and Choleretics</category>
      <mesh-id>D002756</mesh-id>
    </category>
    <category>
      <category>Cholecystokinin, agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cholecystokinin, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Diagnostic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gastrointestinal Agents</category>
      <mesh-id>D005765</mesh-id>
    </category>
    <category>
      <category>Gastrointestinal Hormones</category>
      <mesh-id>D005768</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>OATP1B1/SLCO1B1 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>OATP1B1/SLCO1B1 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>OATP1B3 substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Tests for Pancreatic Function</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V04CK02">
      <level code="V04CK">Tests for pancreatic function</level>
      <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
      <level code="V04">DIAGNOSTIC AGENTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Valsartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Sildenafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Indinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Diethylstilbestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Conjugated estrogens.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00345</drugbank-id>
      <name>Aminohippuric acid</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Aminohippuric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Cerivastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Levothyroxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00520</drugbank-id>
      <name>Caspofungin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Caspofungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Levocarnitine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Ivermectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Simvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00646</drugbank-id>
      <name>Nystatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Nystatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Amprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00778</drugbank-id>
      <name>Roxithromycin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Roxithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Estradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01051</drugbank-id>
      <name>Novobiocin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Novobiocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Ouabain.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01892</drugbank-id>
      <name>Hyperforin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Hyperforin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Cholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Quercetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Taurocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04850</drugbank-id>
      <name>Posizolid</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Posizolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Elacridar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06151</drugbank-id>
      <name>Acetylcysteine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Acetylcysteine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06191</drugbank-id>
      <name>Zosuquidar</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Zosuquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Eltrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Axitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Pitavastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The excretion of Pravastatin can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The excretion of Torasemide can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The excretion of Olmesartan can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The excretion of Liothyronine can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The excretion of Raloxifene can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The excretion of Bosentan can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The excretion of Methotrexate can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The excretion of Enalapril can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The excretion of Sumatriptan can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The excretion of Mycophenolate mofetil can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The excretion of Penicillamine can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The excretion of Repaglinide can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The excretion of Dinoprostone can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The excretion of Fexofenadine can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The excretion of Ezetimibe can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01053</drugbank-id>
      <name>Benzylpenicillin</name>
      <description>The excretion of Benzylpenicillin can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The excretion of Liotrix can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The excretion of Cobimetinib can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06199</drugbank-id>
      <name>Atrasentan</name>
      <description>The excretion of Atrasentan can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The excretion of Ambrisentan can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06721</drugbank-id>
      <name>Gimatecan</name>
      <description>The excretion of Gimatecan can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The excretion of Temocapril can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08884</drugbank-id>
      <name>Gadoxetic acid</name>
      <description>The excretion of Gadoxetic acid can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09137</drugbank-id>
      <name>Technetium Tc-99m mebrofenin</name>
      <description>The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>The excretion of Fimasartan can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The excretion of Paritaprevir can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The excretion of Tenofovir alafenamide can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The excretion of Selexipag can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The excretion of Grazoprevir can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The excretion of Asunaprevir can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The excretion of Elagolix can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The excretion of Voxilaprevir can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The excretion of Letermovir can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The excretion of Levosalbutamol can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The excretion of Glecaprevir can be decreased when combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Rilpivirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Daclatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Sacubitril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09298</drugbank-id>
      <name>Silibinin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Silibinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Velpatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Valspodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Benzbromarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Pibrentasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Estradiol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Estradiol benzoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Estradiol cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Estradiol dienanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Estradiol valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Pexidartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Fedratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Istradefylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15444</drugbank-id>
      <name>Elexacaftor</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Elexacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05016</drugbank-id>
      <name>Ataluren</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Ataluren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06749</drugbank-id>
      <name>Ginsenoside Rb1</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Ginsenoside Rb1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11942</drugbank-id>
      <name>Selinexor</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Selinexor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The excretion of Cholecystokinin can be decreased when combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>Cholecystokinin may decrease the excretion rate of Revefenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The serum concentration of Eluxadoline can be increased when it is combined with Cholecystokinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The excretion of Cholecystokinin can be increased when combined with Apalutamide.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>not water soluble</value>
      <source>http://www.perkinelmer.com/Content/MSDSDatabase/CHOLECYSTOKININ%20OCTAPEPTIDE%20125I-BOLTON-HUNTER%20LABELED%20ASP1%20CCK-8-MSDS_US-English.pdf</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>75</value>
      <source>http://www.perkinelmer.com/Content/MSDSDatabase/CHOLECYSTOKININ%20OCTAPEPTIDE%20125I-BOLTON-HUNTER%20LABELED%20ASP1%20CCK-8-MSDS_US-English.pdf</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2068</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910375</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cholecystokinin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="2">
      <id>BE0000402</id>
      <name>Cholecystokinin receptor type A</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32103</ref-id>
            <pubmed-id>2991034</pubmed-id>
            <citation>Williams JA: Mechanism of action of cholecystokinin: a not atypical brain-gut peptide. Nihon Naibunpi Gakkai Zasshi. 1985 May 20;61(5):533-40.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P32238" source="Swiss-Prot">
        <name>Cholecystokinin receptor type A</name>
        <general-function>Peptide binding</general-function>
        <specific-function>Receptor for cholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. Has a 1000-fold higher affinity for CCK rather than for gastrin. It modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.</specific-function>
        <gene-name>CCKAR</gene-name>
        <locus>4p15.1-p15.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>42-67
78-104
116-137
158-178
211-234
314-334
350-373</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.48</theoretical-pi>
        <molecular-weight>47840.645</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1570</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CCKAR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L13605</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>306491</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>76</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>76</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P32238</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CCKAR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CCK-A receptor</synonym>
          <synonym>CCK1-R</synonym>
          <synonym>CCKRA</synonym>
          <synonym>Cholecystokinin-1 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010278|Cholecystokinin receptor type A
MDVVDSLLVNGSNITPPCELGLENETLFCLDQPRPSKEWQPAVQILLYSLIFLLSVLGNT
LVITVLIRNKRMRTVTNIFLLSLAVSDLMLCLFCMPFNLIPNLLKDFIFGSAVCKTTTYF
MGTSVSVSTFNLVAISLERYGAICKPLQSRVWQTKSHALKVIAATWCLSFTIMTPYPIYS
NLVPFTKNNNQTANMCRFLLPNDVMQQSWHTFLLLILFLIPGIVMMVAYGLISLELYQGI
KFEASQKKSAKERKPSTTSSGKYEDSDGCYLQKTRPPRKLELRQLSTGSSSRANRIRSNS
SAANLMAKKRVIRMLIVIVVLFFLCWMPIFSANAWRAYDTASAERRLSGTPISFILLLSY
TSSCVNPIIYCFMNKRFRLGFMATFPCCPNPGPPGARGEVGEEEEGGTTGASLSRFSYSH
MSASVPPQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010279|Cholecystokinin receptor type A (CCKAR)
ATGGATGTGGTTGACAGCCTTCTTGTGAATGGAAGCAACATCACTCCTCCCTGTGAACTC
GGGCTCGAAAATGAGACGCTTTTCTGCTTGGATCAGCCCCGTCCTTCCAAAGAGTGGCAG
CCAGCGGTGCAGATTCTCTTGTACTCCTTGATATTCCTGCTCAGCGTGCTGGGAAACACG
CTGGTCATCACCGTGCTGATTCGGAACAAGCGGATGCGGACGGTCACCAACATCTTCCTC
CTCTCCCTGGCTGTCAGCGACCTCATGCTCTGTCTCTTCTGCATGCCGTTCAACCTCATC
CCCAATCTGCTCAAGGATTTCATCTTCGGGAGCGCCGTTTGCAAGACCACCACCTACTTC
ATGGGCACCTCTGTGAGTGTATCTACCTTTAATCTGGTAGCCATATCTCTAGAGAGATAT
GGTGCGATTTGCAAACCCTTACAGTCCCGGGTCTGGCAGACAAAATCCCATGCTTTGAAG
GTGATTGCTGCTACCTGGTGCCTTTCCTTTACCATCATGACTCCGTACCCCATTTATAGC
AACTTGGTGCCTTTTACCAAAAATAACAACCAGACCGCGAATATGTGCCGCTTTCTACTG
CCAAATGATGTTATGCAGCAGTCCTGGCACACATTCCTGTTACTCATCCTCTTTCTTATT
CCTGGAATTGTGATGATGGTGGCATATGGATTAATCTCTTTGGAACTCTACCAGGGAATA
AAATTTGAGGCTAGCCAGAAGAAGTCTGCTAAAGAAAGGAAACCTAGCACCACCAGCAGC
GGCAAATATGAGGACAGCGATGGGTGTTACCTGCAAAAGACCAGGCCCCCGAGGAAGCTG
GAGCTCCGGCAGCTGTCCACCGGCAGCAGCAGCAGGGCCAACCGCATCCGGAGTAACAGC
TCCGCAGCCAACCTGATGGCCAAGAAAAGGGTGATCCGCATGCTCATCGTCATCGTGGTC
CTCTTCTTCCTGTGCTGGATGCCCATCTTCAGCGCCAACGCCTGGCGGGCCTACGACACC
GCCTCCGCAGAGCGCCGCCTCTCAGGAACCCCCATTTCCTTCATCCTCCTCCTGTCCTAC
ACCTCCTCCTGCGTCAACCCCATCATCTACTGCTTCATGAACAAACGCTTCCGCCTCGGC
TTCATGGCCACCTTCCCCTGCTGCCCCAATCCTGGTCCCCCAGGGGCGAGGGGAGAGGTG
GGGGAGGAGGAGGAAGGCGGGACCACAGGAGCCTCTCTGTCCAGGTTCTCGTACAGCCAT
ATGAGTGCCTCGGTGCCACCCCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
          <pfam>
            <identifier>PF09193</identifier>
            <name>CholecysA-Rec_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholecystokinin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>actin cytoskeleton reorganization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholecystokinin signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>forebrain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gastric acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pancreatic juice secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of somatostatin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>reduction of food intake in response to dietary excess</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to peptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000036</id>
      <name>RAF proto-oncogene serine/threonine-protein kinase</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1640</ref-id>
            <title>Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.</title>
            <url>https://www.ncbi.nlm.nih.gov/pubmed/12496267</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04049" source="Swiss-Prot">
        <name>RAF proto-oncogene serine/threonine-protein kinase</name>
        <general-function>Protein serine/threonine kinase activity</general-function>
        <specific-function>Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.</specific-function>
        <gene-name>RAF1</gene-name>
        <locus>3p25</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.62</theoretical-pi>
        <molecular-weight>73051.025</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9829</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RAF1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X03484</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35842</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2184</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04049</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RAF1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.11.1</synonym>
          <synonym>cRaf</synonym>
          <synonym>Proto-oncogene c-RAF</synonym>
          <synonym>RAF</synonym>
          <synonym>Raf-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000072|RAF proto-oncogene serine/threonine-protein kinase
MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRV
FLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAAS
LIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKV
PTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTF
NTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNL
SPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSF
GTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIV
TQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGL
TVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYE
LMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFP
QILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009890|RAF proto-oncogene serine/threonine-protein kinase (RAF1)
ATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCC
GTGTTTGATGGCTCCAGCTGCATCTCTCCTACAATAGTTCAGCAGTTTGGCTATCAGCGC
CGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTT
TTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGAC
TGCCTTATGAAAGCACTCAAGGTGAGGGGCCTGCAACCAGAGTGCTGTGCAGTGTTCAGA
CTTCTCCACGAACACAAAGGTAAAAAAGCACGCTTAGATTGGAATACTGATGCTGCGTCT
TTGATTGGAGAAGAACTTCAAGTAGATTTCCTGGATCATGTTCCCCTCACAACACACAAC
TTTGCTCGGAAGACGTTCCTGAAGCTTGCCTTCTGTGACATCTGTCAGAAATTCCTGCTC
AATGGATTTCGATGTCAGACTTGTGGCTACAAATTTCATGAGCACTGTAGCACCAAAGTA
CCTACTATGTGTGTGGACTGGAGTAACATCAGACAACTCTTATTGTTTCCAAATTCCACT
ATTGGTGATAGTGGAGTCCCAGCACTACCTTCTTTGACTATGCGTCGTATGCGAGAGTCT
GTTTCCAGGATGCCTGTTAGTTCTCAGCACAGATATTCTACACCTCACGCCTTCACCTTT
AACACCTCCAGTCCCTCATCTGAAGGTTCCCTCTCCCAGAGGCAGAGGTCGACATCCACA
CCTAATGTCCACATGGTCAGCACCACCCTGCCTGTGGACAGCAGGATGATTGAGGATGCA
ATTCGAAGTCACAGCGAATCAGCCTCACCTTCAGCCCTGTCCAGTAGCCCCAACAATCTG
AGCCCAACAGGCTGGTCACAGCCGAAAACCCCCGTGCCAGCACAAAGAGAGCGGGCACCA
GTATCTGGGACCCAGGAGAAAAACAAAATTAGGCCTCGTGGACAGAGAGATTCAAGCTAT
TATTGGGAAATAGAAGCCAGTGAAGTGATGCTGTCCACTCGGATTGGGTCAGGCTCTTTT
GGAACTGTTTATAAGGGTAAATGGCACGGAGATGTTGCAGTAAAGATCCTAAAGGTTGTC
GACCCAACCCCAGAGCAATTCCAGGCCTTCAGGAATGAGGTGGCTGTTCTGCGCAAAACA
CGGCATGTGAACATTCTGCTTTTCATGGGGTACATGACAAAGGACAACCTGGCAATTGTG
ACCCAGTGGTGCGAGGGCAGCAGCCTCTACAAACACCTGCATGTCCAGGAGACCAAGTTT
CAGATGTTCCAGCTAATTGACATTGCCCGGCAGACGGCTCAGGGAATGGACTATTTGCAT
GCAAAGAACATCATCCATAGAGACATGAAATCCAACAATATATTTCTCCATGAAGGCTTA
ACAGTGAAAATTGGAGATTTTGGTTTGGCAACAGTAAAGTCACGCTGGAGTGGTTCTCAG
CAGGTTGAACAACCTACTGGCTCTGTCCTCTGGATGGCCCCAGAGGTGATCCGAATGCAG
GATAACAACCCATTCAGTTTCCAGTCGGATGTCTACTCCTATGGCATCGTATTGTATGAA
CTGATGACGGGGGAGCTTCCTTATTCTCACATCAACAACCGAGATCAGATCATCTTCATG
GTGGGCCGAGGATATGCCTCCCCAGATCTTAGTAAGCTATATAAGAACTGCCCCAAAGCA
ATGAAGAGGCTGGTAGCTGACTGTGTGAAGAAAGTAAAGGAAGAGAGGCCTCTTTTTCCC
CAGATCCTGTCTTCCATTGAGCTGCTCCAACACTCTCTACCGAAGATCAACCGGAGCGCT
TCCGAGCCATCCTTGCATCGGGCAGCCCACACTGAGGATATCAATGCTTGCACGCTGACC
ACGTCCCCGAGGCTGCCTGTCTTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07714</identifier>
            <name>Pkinase_Tyr</name>
          </pfam>
          <pfam>
            <identifier>PF00130</identifier>
            <name>C1_1</name>
          </pfam>
          <pfam>
            <identifier>PF02196</identifier>
            <name>RBD</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial outer membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>pseudopodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MAP kinase kinase kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein serine/threonine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>death-inducing signaling complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin secretion involved in cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intermediate filament cytoskeleton organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell motility</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of Rho protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to muscle stretch</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>somatic stem cell population maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stimulatory C-type lectin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0001062</id>
      <name>Mitogen-activated protein kinase 3</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1640</ref-id>
            <title>Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.</title>
            <url>https://www.ncbi.nlm.nih.gov/pubmed/12496267</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P27361" source="Swiss-Prot">
        <name>Mitogen-activated protein kinase 3</name>
        <general-function>Phosphatase binding</general-function>
        <specific-function>Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade.</specific-function>
        <gene-name>MAPK3</gene-name>
        <locus>16p11.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.74</theoretical-pi>
        <molecular-weight>43135.16</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6877</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MAPK3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X60188</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31221</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P27361</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MK03_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.11.24</synonym>
          <synonym>ERK-1</synonym>
          <synonym>ERK1</synonym>
          <synonym>ERT2</synonym>
          <synonym>Extracellular signal-regulated kinase 1</synonym>
          <synonym>Insulin-stimulated MAP2 kinase</synonym>
          <synonym>MAP kinase 3</synonym>
          <synonym>MAP kinase isoform p44</synonym>
          <synonym>Microtubule-associated protein 2 kinase</synonym>
          <synonym>p44-ERK1</synonym>
          <synonym>p44-MAPK</synonym>
          <synonym>PRKM3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002115|Mitogen-activated protein kinase 3
MAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFDVGPRYTQLQYIGEGAYGMVSSAY
DHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRASTLEAMRDVYI
VQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDL
KICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLS
NRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSD
SKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFAMELDDLPKERL
KELIFQETARFQPGVLEAP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021655|Mitogen-activated protein kinase 3 (MAPK3)
ATGGCGGCGGCGGCGGCTCAGGGGGGCGGGGGCGGGGAGCCCCGTAGAACCGAGGGGGTC
GGCCCGGGGGTCCCGGGGGAGGTGGAGATGGTGAAGGGGCAGCCGTTCGACGTGGGCCCG
CGCTACACGCAGTTGCAGTACATCGGCGAGGGCGCGTACGGCATGGTCAGCTCGGCCTAT
GACCACGTGCGCAAGACTCGCGTGGCCATCAAGAAGATCAGCCCCTTCGAACATCAGACC
TACTGCCAGCGCACGCTCCGGGAGATCCAGATCCTGCTGCGCTTCCGCCATGAGAATGTC
ATCGGCATCCGAGACATTCTGCGGGCGTCCACCCTGGAAGCCATGAGAGATGTCTACATT
GTGCAGGACCTGATGGAGACTGACCTGTACAAGTTGCTGAAAAGCCAGCAGCTGAGCAAT
GACCATATCTGCTACTTCCTCTACCAGATCCTGCGGGGCCTCAAGTACATCCACTCCGCC
AACGTGCTCCACCGAGATCTAAAGCCCTCCAACCTGCTCATCAACACCACCTGCGACCTT
AAGATTTGTGATTTCGGCCTGGCCCGGATTGCCGATCCTGAGCATGACCACACCGGCTTC
CTGACGGAGTATGTGGCTACGCGCTGGTACCGGGCCCCAGAGATCATGCTGAACTCCAAG
GGCTATACCAAGTCCATCGACATCTGGTCTGTGGGCTGCATTCTGGCTGAGATGCTCTCT
AACCGGCCCATCTTCCCTGGCAAGCACTACCTGGATCAGCTCAACCACATTCTGGGCATC
CTGGGCTCCCCATCCCAGGAGGACCTGAATTGTATCATCAACATGAAGGCCCGAAACTAC
CTACAGTCTCTGCCCTCCAAGACCAAGGTGGCTTGGGCCAAGCTTTTCCCCAAGTCAGAC
TCCAAAGCCCTTGACCTGCTGGACCGGATGTTAACCTTTAACCCCAATAAACGGATCACA
GTGGAGGAAGCGCTGGCTCACCCCTACCTGGAGCAGTACTATGACCCGACGGATGAGGTG
GGCCAGTCCCCAGCAGCAGTGGGGCTGGGGGCAGGGGAGCAGGGGGGCACGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00069</identifier>
            <name>Pkinase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>focal adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>late endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>microtubule cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>pseudopodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>BMP signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cartilage development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>caveolin-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA damage induced protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interleukin-1-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>JAK-STAT cascade involved in growth hormone signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipopolysaccharide-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-independent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apolipoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of histone acetylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of histone phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of telomerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of telomere capping</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of telomere maintenance via telomerase</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of translation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cytoskeleton organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of early endosome to late endosome transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of Golgi inheritance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of stress-activated MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to epidermal growth factor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to exogenous dsRNA</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stress-activated MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 10 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 2 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 3 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 4 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 5 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 9 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR1</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR6</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>trachea formation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription from RNA polymerase I promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase I promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>TRIF-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000953</id>
      <name>Pro-epidermal growth factor</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1640</ref-id>
            <title>Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.</title>
            <url>https://www.ncbi.nlm.nih.gov/pubmed/12496267</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P01133" source="Swiss-Prot">
        <name>Pro-epidermal growth factor</name>
        <general-function>Transmembrane receptor protein tyrosine kinase activator activity</general-function>
        <specific-function>EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941).</specific-function>
        <gene-name>EGF</gene-name>
        <locus>4q25</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1033-1053</transmembrane-regions>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>5.74</theoretical-pi>
        <molecular-weight>133993.12</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3229</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>EGF</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X04571</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31121</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P01133</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EGF_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>EGF</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037104|Pro-epidermal growth factor
MLLTLIILLPVVSKFSFVSLSAPQHWSCPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRID
TEGTNYEQLVVDAGVSVIMDFHYNEKRIYWVDLERQLLQRVFLNGSRQERVCNIEKNVSG
MAINWINEEVIWSNQQEGIITVTDMKGNNSHILLSALKYPANVAVDPVERFIFWSSEVAG
SLYRADLDGVGVKALLETSEKITAVSLDVLDKRLFWIQYNREGSNSLICSCDYDGGSVHI
SKHPTQHNLFAMSLFGDRIFYSTWKMKTIWIANKHTGKDMVRINLHSSFVPLGELKVVHP
LAQPKAEDDTWEPEQKLCKLRKGNCSSTVCGQDLQSHLCMCAEGYALSRDRKYCEDVNEC
AFWNHGCTLGCKNTPGSYYCTCPVGFVLLPDGKRCHQLVSCPRNVSECSHDCVLTSEGPL
CFCPEGSVLERDGKTCSGCSSPDNGGCSQLCVPLSPVSWECDCFPGYDLQLDEKSCAASG
PQPFLLFANSQDIRHMHFDGTDYGTLLSQQMGMVYALDHDPVENKIYFAHTALKWIERAN
MDGSQRERLIEEGVDVPEGLAVDWIGRRFYWTDRGKSLIGRSDLNGKRSKIITKENISQP
RGIAVHPMAKRLFWTDTGINPRIESSSLQGLGRLVIASSDLIWPSGITIDFLTDKLYWCD
AKQSVIEMANLDGSKRRRLTQNDVGHPFAVAVFEDYVWFSDWAMPSVMRVNKRTGKDRVR
LQGSMLKPSSLVVVHPLAKPGADPCLYQNGGCEHICKKRLGTAWCSCREGFMKASDGKTC
LALDGHQLLAGGEVDLKNQVTPLDILSKTRVSEDNITESQHMLVAEIMVSDQDDCAPVGC
SMYARCISEGEDATCQCLKGFAGDGKLCSDIDECEMGVPVCPPASSKCINTEGGYVCRCS
EGYQGDGIHCLDIDECQLGEHSCGENASCTNTEGGYTCMCAGRLSEPGLICPDSTPPPHL
REDDHHYSVRNSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWW
ELRHAGHGQQQKVIVVAVCVVVLVMLLLLSLWGAHYYRTQKLLSKNPKNPYEESSRDVRS
RRPADTEDGMSSCPQPWFVVIKEHQDLKNGGQPVAGEDGQAADGSMQPTSWRQEPQLCGM
GTEQGCWIPVSSDKGSCPQVMERSFHMPSYGTQTLEGGVEKPHSLLSANPLWQQRALDPP
HQMELTQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019041|Pro-epidermal growth factor (EGF)
ATGCTGCTCACTCTTATCATTCTGTTGCCAGTAGTTTCAAAATTTAGTTTTGTTAGTCTC
TCAGCACCGCAGCACTGGAGCTGTCCTGAAGGTACTCTCGCAGGAAATGGGAATTCTACT
TGTGTGGGTCCTGCACCCTTCTTAATTTTCTCCCATGGAAATAGTATCTTTAGGATTGAC
ACAGAAGGAACCAATTATGAGCAATTGGTGGTGGATGCTGGTGTCTCAGTGATCATGGAT
TTTCATTATAATGAGAAAAGAATCTATTGGGTGGATTTAGAAAGACAACTTTTGCAAAGA
GTTTTTCTGAATGGGTCAAGGCAAGAGAGAGTATGTAATATAGAGAAAAATGTTTCTGGA
ATGGCAATAAATTGGATAAATGAAGAAGTTATTTGGTCAAATCAACAGGAAGGAATCATT
ACAGTAACAGATATGAAAGGAAATAATTCCCACATTCTTTTAAGTGCTTTAAAATATCCT
GCAAATGTAGCAGTTGATCCAGTAGAAAGGTTTATATTTTGGTCTTCAGAGGTGGCTGGA
AGCCTTTATAGAGCAGATCTCGATGGTGTGGGAGTGAAGGCTCTGTTGGAGACATCAGAG
AAAATAACAGCTGTGTCATTGGATGTGCTTGATAAGCGGCTGTTTTGGATTCAGTACAAC
AGAGAAGGAAGCAATTCTCTTATTTGCTCCTGTGATTATGATGGAGGTTCTGTCCACATT
AGTAAACATCCAACACAGCATAATTTGTTTGCAATGTCCCTTTTTGGTGACCGTATCTTC
TATTCAACATGGAAAATGAAGACAATTTGGATAGCCAACAAACACACTGGAAAGGACATG
GTTAGAATTAACCTCCATTCATCATTTGTACCACTTGGTGAACTGAAAGTAGTGCATCCA
CTTGCACAACCCAAGGCAGAAGATGACACTTGGGAGCCTGAGCAGAAACTTTGCAAATTG
AGGAAAGGAAACTGCAGCAGCACTGTGTGTGGGCAAGACCTCCAGTCACACTTGTGCATG
TGTGCAGAGGGATACGCCCTAAGTCGAGACCGGAAGTACTGTGAAGATGTTAATGAATGT
GCTTTTTGGAATCATGGCTGTACTCTTGGGTGTAAAAACACCCCTGGATCCTATTACTGC
ACGTGCCCTGTAGGATTTGTTCTGCTTCCTGATGGGAAACGATGTCATCAACTTGTTTCC
TGTCCACGCAATGTGTCTGAATGCAGCCATGACTGTGTTCTGACATCAGAAGGTCCCTTA
TGTTTCTGTCCTGAAGGCTCAGTGCTTGAGAGAGATGGGAAAACATGTAGCGGTTGTTCC
TCACCCGATAATGGTGGATGTAGCCAGCTCTGCGTTCCTCTTAGCCCAGTATCCTGGGAA
TGTGATTGCTTTCCTGGGTATGACCTACAACTGGATGAAAAAAGCTGTGCAGCTTCAGGA
CCACAACCATTTTTGCTGTTTGCCAATTCTCAAGATATTCGACACATGCATTTTGATGGA
ACAGACTATGGAACTCTGCTCAGCCAGCAGATGGGAATGGTTTATGCCCTAGATCATGAC
CCTGTGGAAAATAAGATATACTTTGCCCATACAGCCCTGAAGTGGATAGAGAGAGCTAAT
ATGGATGGTTCCCAGCGAGAAAGGCTTATTGAGGAAGGAGTAGATGTGCCAGAAGGTCTT
GCTGTGGACTGGATTGGCCGTAGATTCTATTGGACAGACAGAGGGAAATCTCTGATTGGA
AGGAGTGATTTAAATGGGAAACGTTCCAAAATAATCACTAAGGAGAACATCTCTCAACCA
CGAGGAATTGCTGTTCATCCAATGGCCAAGAGATTATTCTGGACTGATACAGGGATTAAT
CCACGAATTGAAAGTTCTTCCCTCCAAGGCCTTGGCCGTCTGGTTATAGCCAGCTCTGAT
CTAATCTGGCCCAGTGGAATAACGATTGACTTCTTAACTGACAAGTTGTACTGGTGCGAT
GCCAAGCAGTCTGTGATTGAAATGGCCAATCTGGATGGTTCAAAACGCCGAAGACTTACC
CAGAATGATGTAGGTCACCCATTTGCTGTAGCAGTGTTTGAGGATTATGTGTGGTTCTCA
GATTGGGCTATGCCATCAGTAATGAGAGTAAACAAGAGGACTGGCAAAGATAGAGTACGT
CTCCAAGGCAGCATGCTGAAGCCCTCATCACTGGTTGTGGTTCATCCATTGGCAAAACCA
GGAGCAGATCCCTGCTTATATCAAAACGGAGGCTGTGAACATATTTGCAAAAAGAGGCTT
GGAACTGCTTGGTGTTCGTGTCGTGAAGGTTTTATGAAAGCCTCAGATGGGAAAACGTGT
CTGGCTCTGGATGGTCATCAGCTGTTGGCAGGTGGTGAAGTTGATCTAAAGAACCAAGTA
ACACCATTGGACATCTTGTCCAAGACTAGAGTGTCAGAAGATAACATTACAGAATCTCAA
CACATGCTAGTGGCTGAAATCATGGTGTCAGATCAAGATGACTGTGCTCCTGTGGGATGC
AGCATGTATGCTCGGTGTATTTCAGAGGGAGAGGATGCCACATGTCAGTGTTTGAAAGGA
TTTGCTGGGGATGGAAAACTATGTTCTGATATAGATGAATGTGAGATGGGTGTCCCAGTG
TGCCCCCCTGCCTCCTCCAAGTGCATCAACACCGAAGGTGGTTATGTCTGCCGGTGCTCA
GAAGGCTACCAAGGAGATGGGATTCACTGTCTTGACTCTACTCCACCCCCTCACCTCAGG
GAAGATGACCACCACTATTCCGTAAGAAATAGTGACTCTGAATGTCCCCTGTCCCACGAT
GGGTACTGCCTCCATGATGGTGTGTGCATGTATATTGAAGCATTGGACAAGTATGCATGC
AACTGTGTTGTTGGCTACATCGGGGAGCGATGTCAGTACCGAGACCTGAAGTGGTGGGAA
CTGCGCCACGCTGGCCACGGGCAGCAGCAGAAGGTCATCGTGGTGGCTGTCTGCGTGGTG
GTGCTTGTCATGCTGCTCCTCCTGAGCCTGTGGGGGGCCCACTACTACAGGACTCAGAAG
CTGCTATCGAAAAACCCAAAGAATCCTTATGAGGAGTCGAGCAGAGATGTGAGGAGTCGC
AGGCCTGCTGACACTGAGGATGGGATGTCCTCTTGCCCTCAACCTTGGTTTGTGGTTATA
AAAGAACACCAAGACCTCAAGAATGGGGGTCAACCAGTGGCTGGTGAGGATGGCCAGGCA
GCAGATGGGTCAATGCAACCAACTTCATGGAGGCAGGAGCCCCAGTTATGTGGAATGGGC
ACAGAGCAAGGCTGCTGGATTCCAGTATCCAGTGATAAGGGCTCCTGTCCCCAGGTAATG
GAGCGAAGCTTTCATATGCCCTCCTATGGGACACAGACCCTTGAAGGGGGTGTCGAGAAG
CCCCATTCTCTCCTATCAGCTAACCCATTATGGCAACAAAGGGCCCTGGACCCACCACAC
CAAATGGAGCTGACTCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00008</identifier>
            <name>EGF</name>
          </pfam>
          <pfam>
            <identifier>PF07645</identifier>
            <name>EGF_CA</name>
          </pfam>
          <pfam>
            <identifier>PF00058</identifier>
            <name>Ldl_recept_b</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epidermal growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>growth factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane receptor protein tyrosine kinase activator activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of transmembrane receptor protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>branching morphogenesis of an epithelial tube</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland alveolus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cholesterol efflux</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of catenin import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cerebellar granule cell precursor proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epidermal growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of hyaluronan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-threonine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein localization to cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>STAT protein import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0000872</id>
      <name>Protein kinase C beta type</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1640</ref-id>
            <title>Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.</title>
            <url>https://www.ncbi.nlm.nih.gov/pubmed/12496267</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05771" source="Swiss-Prot">
        <name>Protein kinase C beta type</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity. Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A. In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. May participate in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis (By similarity). Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription.</specific-function>
        <gene-name>PRKCB</gene-name>
        <locus>16p11.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.0</theoretical-pi>
        <molecular-weight>76868.45</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9395</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PRKCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M13975</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189969</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1483</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05771</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>KPCB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.11.13</synonym>
          <synonym>PKC-B</synonym>
          <synonym>PKCB</synonym>
          <synonym>PRKCB1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001738|Protein kinase C beta type
MADPAAGPPPSEGEESTVRFARKGALRQKNVHEVKNHKFTARFFKQPTFCSHCTDFIWGF
GKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPASDDPRSKHKFKIHTYSSPTFCDHCGS
LLYGLIHQGMKCDTCMMNVHKRCVMNVPSLCGTDHTERRGRIYIQAHIDRDVLIVLVRDA
KNLVPMDPNGLSDPYVKLKLIPDPKSESKQKTKTIKCSLNPEWNETFRFQLKESDKDRRL
SVEIWDWDLTSRNDFMGSLSFGISELQKASVDGWFKLLSQEEGEYFNVPVPPEGSEANEE
LRQKFERAKISQGTKVPEEKTTNTVSKFDNNGNRDRMKLTDFNFLMVLGKGSFGKVMLSE
RKGTDELYAVKILKKDVVIQDDDVECTMVEKRVLALPGKPPFLTQLHSCFQTMDRLYFVM
EYVNGGDLMYHIQQVGRFKEPHAVFYAAEIAIGLFFLQSKGIIYRDLKLDNVMLDSEGHI
KIADFGMCKENIWDGVTTKTFCGTPDYIAPEIIAYQPYGKSVDWWAFGVLLYEMLAGQAP
FEGEDEDELFQSIMEHNVAYPKSMSKEAVAICKGLMTKHPGKRLGCGPEGERDIKEHAFF
RYIDWEKLERKEIQPPYKPKARDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGF
SYTNPEFVINV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010616|Protein kinase C beta type (PRKCB)
ATGGCTGACCCGGCTGCGGGGCCGCCGCCGAGCGAGGGCGAGGAGAGCACCGTGCGCTTC
GCCCGCAAAGGCGCCCTCCGGCAGAAGAACGTGCATGAGGTCAAGAACCACAAATTCACC
GCCCGCTTCTTCAAGCAGCCCACCTTCTGCAGCCACTGCACCGACTTCATCTGGGGCTTC
GGGAAGCAGGGATTCCAGTGCCAAGTTTGCTGCTTTGTGGTGCACAAGCGGTGCCATGAA
TTTGTCACATTCTCCTGCCCTGGCGCTGACAAGGGTCCAGCCTCCGATGACCCCCGCAGC
AAACACAAGTTTAAGATCCACACGTACTCCAGCCCCACGTTTTGTGACCACTGTGGGTCA
CTGCTGTATGGACTCATCCACCAGGGGATGAAATGTGACACCTGCATGATGAATGTGCAC
AAGCGCTGCGTGATGAATGTTCCCAGCCTGTGTGGCACGGACCACACGGAGCGCCGCGGC
CGCATCTACATCCAGGCCCACATCGACAGGGACGTCCTCATTGTCCTCGTAAGAGATGCT
AAAAACCTTGTACCTATGGACCCCAATGGCCTGTCAGATCCCTACGTAAAACTGAAACTG
ATTCCCGATCCCAAAAGTGAGAGCAAACAGAAGACCAAAACCATCAAATGCTCCCTCAAC
CCTGAGTGGAATGAGACATTTAGATTTCAGCTGAAAGAATCGGACAAAGACAGAAGACTG
TCAGTAGAGATTTGGGATTGGGATTTGACCAGCAGGAATGACTTCATGGGATCTTTGTCC
TTTGGGATTTCTGAACTTCAGAAAGCCAGTGTTGATGGCTGGTTTAAGTTACTGAGCCAG
GAGGAAGGCGAGTACTTCAATGTGCCTGTGCCACCAGAAGGAAGTGAGGCCAATGAAGAA
CTGCGGCAGAAATTTGAGAGGGCCAAGATCAGTCAGGGAACCAAGGTCCCGGAAGAAAAG
ACGACCAACACTGTCTCCAAATTTGACAACAATGGCAACAGAGACCGGATGAAACTGACC
GATTTTAACTTCCTAATGGTGCTGGGGAAAGGCAGCTTTGGCAAGGTCATGCTTTCAGAA
CGAAAAGGCACAGATGAGCTCTATGCTGTGAAGATCCTGAAGAAGGACGTTGTGATCCAA
GATGATGACGTGGAGTGCACTATGGTGGAGAAGCGGGTGTTGGCCCTGCCTGGGAAGCCG
CCCTTCCTGACCCAGCTCCACTCCTGCTTCCAGACCATGGACCGCCTGTACTTTGTGATG
GAGTACGTGAATGGGGGCGACCTCATGTATCACATCCAGCAAGTCGGCCGGTTCAAGGAG
CCCCATGCTGTATTTTACGCTGCAGAAATTGCCATCGGTCTGTTCTTCTTACAGAGTAAG
GGCATCATTTACCGTGACCTAAAACTTGACAACGTGATGCTCGATTCTGAGGGACACATC
AAGATTGCCGATTTTGGCATGTGTAAGGAAAACATCTGGGATGGGGTGACAACCAAGACA
TTCTGTGGCACTCCAGACTACATCGCCCCCGAGATAATTGCTTATCAGCCCTATGGGAAG
TCCGTGGATTGGTGGGCATTTGGAGTCCTGCTGTATGAAATGTTGGCTGGGCAGGCACCC
TTTGAAGGGGAGGATGAAGATGAACTCTTCCAATCCATCATGGAACACAACGTAGCCTAT
CCCAAGTCTATGTCCAAGGAAGCTGTGGCCATCTGCAAAGGGCTGATGACCAAACACCCA
GGCAAACGTCTGGGTTGTGGACCTGAAGGCGAACGTGATATCAAAGAGCATGCATTTTTC
CGGTATATTGATTGGGAGAAACTTGAACGCAAAGAGATCCAGCCCCCTTATAAGCCAAAA
GCTTGTGGGCGAAATGCTGAAAACTTCGACCGATTTTTCACCCGCCATCCACCAGTCCTA
ACACCTCCCGACCAGGAAGTCATCAGGAATATTGACCAATCAGAATTCGAAGGATTTTCC
TTTGTTAACTCTGAATTTTTAAAACCCGAAGTCAAGAGCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00069</identifier>
            <name>Pkinase</name>
          </pfam>
          <pfam>
            <identifier>PF00130</identifier>
            <name>C1_1</name>
          </pfam>
          <pfam>
            <identifier>PF00433</identifier>
            <name>Pkinase_C</name>
          </pfam>
          <pfam>
            <identifier>PF00168</identifier>
            <name>C2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androgen receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histone kinase activity (H3-T6 specific)</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-dependent nuclear receptor transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase C binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein serine/threonine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adaptive immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to carbohydrate stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>histone H3-T6 phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic nuclear envelope disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucose transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of B cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0001158</id>
      <name>Gastrin/cholecystokinin type B receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P32239" source="Swiss-Prot">
        <name>Gastrin/cholecystokinin type B receptor</name>
        <general-function>Type b gastrin/cholecystokinin receptor binding</general-function>
        <specific-function>Receptor for gastrin and cholecystokinin. The CKK-B receptors occur throughout the central nervous system where they modulate anxiety, analgesia, arousal, and neuroleptic activity. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.Isoform 2 is constitutively activated and may regulate cancer cell proliferation via a gastrin-independent mechanism.</specific-function>
        <gene-name>CCKBR</gene-name>
        <locus>11p15.4</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>58-79
88-109
132-150
171-189
220-242
334-355
374-394</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.24</theoretical-pi>
        <molecular-weight>48418.51</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1571</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CCKBR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L08112</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>306489</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>77</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>77</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P32239</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GASR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CCK-B receptor</synonym>
          <synonym>CCK2-R</synonym>
          <synonym>CCKRB</synonym>
          <synonym>Cholecystokinin-2 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002303|Gastrin/cholecystokinin type B receptor
MELLKLNRSVQGTGPGPGASLCRPGAPLLNSSSVGNLSCEPPRIRGAGTRELELAIRITL
YAVIFLMSVGGNMLIIVVLGLSRRLRTVTNAFLLSLAVSDLLLAVACMPFTLLPNLMGTF
IFGTVICKAVSYLMGVSVSVSTLSLVAIALERYSAICRPLQARVWQTRSHAARVIVATWL
LSGLLMVPYPVYTVVQPVGPRVLQCVHRWPSARVRQTWSVLLLLLLFFIPGVVMAVAYGL
ISRELYLGLRFDGDSDSDSQSRVRNQGGLPGAVHQNGRCRPETGAVGEDSDGCYVQLPRS
RPALELTALTAPGPGSGSRPTQAKLLAKKRVVRMLLVIVVLFFLCWLPVYSANTWRAFDG
PGAHRALSGAPISFIHLLSYASACVNPLVYCFMHRRFRQACLETCARCCPRPPRARPRAL
PDEDPPTPSIASLSRLSYTTISTLGPG</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019073|Gastrin/cholecystokinin type B receptor (CCKBR)
ATGGAGCTGCTAAAGCTGAACCGGAGCGTGCAGGGAACCGGACCCGGGCCGGGGGCTTCC
CTGTGCCGCCCGGGGGCGCCTCTCCTCAACAGCAGCAGTGTGGGCAACCTCAGCTGCGAG
CCCCCTCGCATTCGCGGAGCCGGGACACGAGAATTGGAGCTGGCCATTAGAATCACTCTT
TACGCAGTGATCTTCCTGATGAGCGTTGGAGGAAATATGCTCATCATCGTGGTCCTGGGA
CTGAGCCGCCGCCTGAGGACTGTCACCAATGCCTTCCTCCTCTCACTGGCAGTCAGCGAC
CTCCTGCTGGCTGTGGCTTGCATGCCCTTCACCCTCCTGCCCAATCTCATGGGCACATTC
ATCTTTGGCACCGTCATCTGCAAGGCGGTTTCCTACCTCATGGGGGTGTCTGTGAGTGTG
TCCACGCTAAGCCTCGTGGCCATCGCACTGGAGCGGTACAGCGCCATCTGCCGACCACTG
CAGGCACGAGTGTGGCAGACGCGCTCCCACGCGGCTCGCGTGATTGTAGCCACGTGGCTG
CTGTCCGGACTACTCATGGTGCCCTACCCCGTGTACACTGTCGTGCAACCAGTGGGGCCT
CGTGTGCTGCAGTGCGTGCATCGCTGGCCCAGTGCGCGGGTCCGCCAGACCTGGTCCGTA
CTGCTGCTTCTGCTCTTGTTCTTCATCCCGGGTGTGGTTATGGCCGTGGCCTACGGGCTT
ATCTCTCGCGAGCTCTACTTAGGGCTTCGCTTTGACGGCGACAGTGACAGCGACAGCCAA
AGCAGGGTCCGAAACCAAGGCGGGCTGCCAGGGGCTGTTCACCAGAACGGGCGTTGCCGG
CCTGAGACTGGCGCGGTTGGCGAAGACAGCGATGGCTGCTACGTGCAACTTCCACGTTCC
CGGCCTGCCCTGGAGCTGACGGCGCTGACGGCTCCTGGGCCGGGATCCGGCTCCCGGCCC
ACCCAGGCCAAGCTGCTGGCTAAGAAGCGCGTGGTGCGAATGTTGCTGGTGATCGTTGTG
CTTTTTTTTCTGTGTTGGTTGCCAGTTTATAGTGCCAACACGTGGCGCGCCTTTGATGGC
CCGGGTGCACACCGAGCACTCTCGGGTGCTCCTATCTCCTTCATTCACTTGCTGAGCTAC
GCCTCGGCCTGTGTCAACCCCCTGGTCTACTGCTTCATGCACCGTCGCTTTCGCCAGGCC
TGCCTGGAAACTTGCGCTCGCTGCTGCCCCCGGCCTCCACGAGCTCGCCCCAGGGCTCTT
CCCGATGAGGACCCTCCCACTCCCTCCATTGCTTCGCTGTCCAGGCTTAGCTACACCACC
ATCAGCACACTGGGCCCTGGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholecystokinin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>gastrin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>type B gastrin/cholecystokinin receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholecystokinin signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gastric acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0003659</id>
      <name>Solute carrier organic anion transporter family member 1B3</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17892</ref-id>
            <pubmed-id>11677211</pubmed-id>
            <citation>Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA: Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology. 2001 Nov;121(5):1185-90.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9NPD5" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 1B3</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.</specific-function>
        <gene-name>SLCO1B3</gene-name>
        <locus>12p12</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>29-48
68-88
95-119
169-197
217-237
256-280
332-353
374-397
402-425
538-560
570-595
630-647</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.95</theoretical-pi>
        <molecular-weight>77402.175</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10961</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ251506</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>9187497</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1221</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NPD5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO1B3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Liver-specific organic anion transporter 2</synonym>
          <synonym>LST-2</synonym>
          <synonym>LST2</synonym>
          <synonym>OATP-8</synonym>
          <synonym>OATP1B3</synonym>
          <synonym>OATP8</synonym>
          <synonym>Organic anion transporter 8</synonym>
          <synonym>Organic anion-transporting polypeptide 8</synonym>
          <synonym>SLC21A8</synonym>
          <synonym>Solute carrier family 21 member 8</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007032|Solute carrier organic anion transporter family member 1B3
MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKISITQIERRFD
ISSSLAGLIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCLLMGTGSILTSLPHFFMGY
YRYSKETHINPSENSTSSLSTCLINQTLSFNGTSPEIVEKDCVKESGSHMWIYVFMGNML
RGIGETPIVPLGISYIDDFAKEGHSSLYLGSLNAIGMIGPVIGFALGSLFAKMYVDIGYV
DLSTIRITPKDSRWVGAWWLGFLVSGLFSIISSIPFFFLPKNPNKPQKERKISLSLHVLK
TNDDRNQTANLTNQGKNVTKNVTGFFQSLKSILTNPLYVIFLLLTLLQVSSFIGSFTYVF
KYMEQQYGQSASHANFLLGIITIPTVATGMFLGGFIIKKFKLSLVGIAKFSFLTSMISFL
FQLLYFPLICESKSVAGLTLTYDGNNSVASHVDVPLSYCNSECNCDESQWEPVCGNNGIT
YLSPCLAGCKSSSGIKKHTVFYNCSCVEVTGLQNRNYSAHLGECPRDNTCTRKFFIYVAI
QVINSLFSATGGTTFILLTVKIVQPELKALAMGFQSMVIRTLGGILAPIYFGALIDKTCM
KWSTNSCGAQGACRIYNSVFFGRVYLGLSIALRFPALVLYIVFIFAMKKKFQGKDTKASD
NERKVMDEANLEFLNNGEHFVPSAGTDSKTCNLDMQDNAAAN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012544|Solute carrier organic anion transporter family member 1B3 (SLCO1B3)
ATGGACCAACATCAACATTTGAATAAAACAGCAGAGTCAGCATCTTCAGAGAAAAAGAAA
ACAAGACGCTGCAATGGATTCAAGATGTTCTTGGCAGCCCTGTCATTCAGCTATATTGCT
AAAGCACTAGGTGGAATCATTATGAAAATTTCCATCACTCAAATAGAAAGGAGATTTGAC
ATATCCTCTTCTCTTGCTGGTTTAATTGATGGAAGCTTTGAAATTGGAAATTTGCTTGTG
ATTGTATTTGTAAGTTACTTTGGATCTAAACTACACAGACCGAAGTTAATTGGAATTGGT
TGTCTCCTTATGGGAACTGGAAGTATTTTGACATCTTTACCACATTTCTTCATGGGATAT
TATAGGTATTCTAAAGAAACCCATATTAATCCATCAGAAAATTCAACATCAAGTTTATCA
ACCTGTTTAATTAATCAAACCTTATCATTCAATGGAACATCACCTGAGATAGTAGAAAAA
GATTGTGTAAAGGAATCTGGGTCACACATGTGGATCTATGTCTTCATGGGGAATATGCTT
CGTGGCATAGGGGAAACCCCCATAGTACCATTGGGGATTTCATACATTGATGATTTTGCA
AAAGAAGGACATTCTTCCTTGTATTTAGGTAGTTTGAATGCAATAGGAATGATTGGTCCA
GTCATTGGCTTTGCACTGGGATCTCTGTTTGCTAAAATGTACGTGGATATTGGATATGTA
GATCTGAGCACTATCAGAATAACTCCTAAGGACTCTCGTTGGGTTGGAGCTTGGTGGCTT
GGTTTCCTTGTGTCTGGACTATTTTCCATTATTTCTTCCATACCATTTTTTTTCTTGCCG
AAAAATCCAAATAAACCACAAAAAGAAAGAAAAATTTCACTATCATTGCATGTGCTGAAA
ACAAATGATGATAGAAATCAAACAGCTAATTTGACCAACCAAGGAAAAAATGTTACCAAA
AATGTGACTGGTTTTTTCCAGTCTTTGAAAAGCATCCTTACCAATCCCCTGTATGTTATA
TTTCTGCTTTTGACATTGTTACAAGTAAGCAGCTTTATTGGTTCTTTTACTTACGTCTTT
AAATATATGGAGCAACAGTACGGTCAGTCTGCATCTCATGCTAACTTTTTGTTGGGAATC
ATAACCATTCCTACGGTTGCAACTGGAATGTTTTTAGGAGGATTTATCATTAAAAAATTC
AAATTGTCTTTAGTTGGAATTGCCAAATTTTCATTTCTTACTTCGATGATATCCTTCTTG
TTTCAACTTCTATATTTCCCTCTAATCTGCGAAAGCAAATCAGTTGCCGGCCTAACCTTG
ACCTATGATGGAAATAATTCAGTGGCATCTCATGTAGATGTACCACTTTCTTATTGCAAC
TCAGAGTGCAATTGTGATGAAAGTCAGTGGGAACCAGTCTGTGGGAACAATGGAATAACT
TACCTGTCACCTTGTCTAGCAGGATGCAAATCCTCAAGTGGTATTAAAAAGCATACAGTG
TTTTATAACTGTAGTTGTGTGGAAGTAACTGGTCTCCAGAACAGAAATTACTCAGCACAC
TTGGGTGAATGCCCAAGAGATAATACTTGTACAAGGAAATTTTTCATCTATGTTGCAATT
CAAGTCATAAACTCTTTGTTCTCTGCAACAGGAGGTACCACATTTATCTTGTTGACTGTG
AAGATTGTTCAACCTGAATTGAAAGCACTTGCAATGGGTTTCCAGTCAATGGTTATAAGA
ACACTAGGAGGAATTCTAGCTCCAATATATTTTGGGGCTCTGATTGATAAAACATGTATG
AAGTGGTCCACCAACAGCTGTGGAGCACAAGGAGCTTGTAGGATATATAATTCCGTATTT
TTTGGAAGGGTCTACTTGGGCTTATCTATAGCTTTAAGATTCCCAGCACTTGTTTTATAT
ATTGTTTTCATTTTTGCTATGAAGAAAAAATTTCAAGGAAAAGATACCAAGGCATCGGAC
AATGAAAGAAAAGTAATGGATGAAGCAAACTTAGAATTCTTAAATAATGGTGAACATTTT
GTACCTTCTGCTGGAACAGATAGTAAAACATGTAATTTGGACATGCAAGACAATGCTGCT
GCCAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="8">
      <id>BE0001004</id>
      <name>Solute carrier organic anion transporter family member 1B1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18357</ref-id>
            <pubmed-id>22541068</pubmed-id>
            <citation>Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y6L6" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 1B1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.</specific-function>
        <gene-name>SLCO1B1</gene-name>
        <locus>12p</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>29-48
68-88
95-119
169-197
217-237
256-280
332-353
374-397
402-425
538-560
570-595
630-647</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.68</theoretical-pi>
        <molecular-weight>76447.99</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLCO1B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF060500</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5051630</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1220</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y6L6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO1B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Liver-specific organic anion transporter 1</synonym>
          <synonym>LST-1</synonym>
          <synonym>LST1</synonym>
          <synonym>OATP-2</synonym>
          <synonym>OATP-C</synonym>
          <synonym>OATP1B1</synonym>
          <synonym>OATP2</synonym>
          <synonym>OATPC</synonym>
          <synonym>SLC21A6</synonym>
          <synonym>Sodium-independent organic anion-transporting polypeptide 2</synonym>
          <synonym>Solute carrier family 21 member 6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010701|Solute carrier organic anion transporter family member 1B1
MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKSSIIHIERRFE
ISSSLVGFIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCFIMGIGGVLTALPHFFMGY
YRYSKETNINSSENSTSTLSTCLINQILSLNRASPEIVGKGCLKESGSYMWIYVFMGNML
RGIGETPIVPLGLSYIDDFAKEGHSSLYLGILNAIAMIGPIIGFTLGSLFSKMYVDIGYV
DLSTIRITPTDSRWVGAWWLNFLVSGLFSIISSIPFFFLPQTPNKPQKERKASLSLHVLE
TNDEKDQTANLTNQGKNITKNVTGFFQSFKSILTNPLYVMFVLLTLLQVSSYIGAFTYVF
KYVEQQYGQPSSKANILLGVITIPIFASGMFLGGYIIKKFKLNTVGIAKFSCFTAVMSLS
FYLLYFFILCENKSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNNGIT
YISPCLAGCKSSSGNKKPIVFYNCSCLEVTGLQNRNYSAHLGECPRDDACTRKFYFFVAI
QVLNLFFSALGGTSHVMLIVKIVQPELKSLALGFHSMVIRALGGILAPIYFGALIDTTCI
KWSTNNCGTRGSCRTYNSTSFSRVYLGLSSMLRVSSLVLYIILIYAMKKKYQEKDINASE
NGSVMDEANLESLNKNKHFVPSAGADSETHC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010702|Solute carrier organic anion transporter family member 1B1 (SLCO1B1)
ATGGACCAAAATCAACATTTGAATAAAACAGCAGAGGCACAACCTTCAGAGAATAAGAAA
ACAAGATACTGCAATGGATTGAAGATGTTCTTGGCAGCTCTGTCACTCAGCTTTATTGCT
AAGACACTAGGTGCAATTATTATGAAAAGTTCCATCATTCATATAGAACGGAGATTTGAG
ATATCCTCTTCTCTTGTTGGTTTTATTGACGGAAGCTTTGAAATTGGAAATTTGCTTGTG
ATTGTATTTGTGAGTTACTTTGGATCCAAACTACATAGACCAAAGTTAATTGGAATCGGT
TGTTTCATTATGGGAATTGGAGGTGTTTTGACTGCTTTGCCACATTTCTTCATGGGATAT
TACAGGTATTCTAAAGAAACTAATATCAATTCATCAGAAAATTCAACATCGACCTTATCC
ACTTGTTTAATTAATCAAATTTTATCACTCAATAGAGCATCACCTGAGATAGTGGGAAAA
GGTTGTTTAAAGGAATCTGGGTCATACATGTGGATATATGTGTTCATGGGTAATATGCTT
CGTGGAATAGGGGAGACTCCCATAGTACCATTGGGGCTTTCTTACATTGATGATTTCGCT
AAAGAAGGACATTCTTCTTTGTATTTAGGTATATTGAATGCAATAGCAATGATTGGTCCA
ATCATTGGCTTTACCCTGGGATCTCTGTTTTCTAAAATGTACGTGGATATTGGATATGTA
GATCTAAGCACTATCAGGATAACTCCTACTGATTCTCGATGGGTTGGAGCTTGGTGGCTT
AATTTCCTTGTGTCTGGACTATTCTCCATTATTTCTTCCATACCATTCTTTTTCTTGCCC
CAAACTCCAAATAAACCACAAAAAGAAAGAAAAGCTTCACTGTCTTTGCATGTGCTGGAA
ACAAATGATGAAAAGGATCAAACAGCTAATTTGACCAATCAAGGAAAAAATATTACCAAA
AATGTGACTGGTTTTTTCCAGTCTTTTAAAAGCATCCTTACTAATCCCCTGTATGTTATG
TTTGTGCTTTTGACGTTGTTACAAGTAAGCAGCTATATTGGTGCTTTTACTTATGTCTTC
AAATACGTAGAGCAACAGTATGGTCAGCCTTCATCTAAGGCTAACATCTTATTGGGAGTC
ATAACCATACCTATTTTTGCAAGTGGAATGTTTTTAGGAGGATATATCATTAAAAAATTC
AAACTGAACACCGTTGGAATTGCCAAATTCTCATGTTTTACTGCTGTGATGTCATTGTCC
TTTTACCTATTATATTTTTTCATACTCTGTGAAAACAAATCAGTTGCCGGACTAACCATG
ACCTATGATGGAAATAATCCAGTGACATCTCATAGAGATGTACCACTTTCTTATTGCAAC
TCAGACTGCAATTGTGATGAAAGTCAATGGGAACCAGTCTGTGGAAACAATGGAATAACT
TACATCTCACCCTGTCTAGCAGGTTGCAAATCTTCAAGTGGCAATAAAAAGCCTATAGTG
TTTTACAACTGCAGTTGTTTGGAAGTAACTGGTCTCCAGAACAGAAATTACTCAGCCCAT
TTGGGTGAATGCCCAAGAGATGATGCTTGTACAAGGAAATTTTACTTTTTTGTTGCAATA
CAAGTCTTGAATTTATTTTTCTCTGCACTTGGAGGCACCTCACATGTCATGCTGATTGTT
AAAATTGTTCAACCTGAATTGAAATCACTTGCACTGGGTTTCCACTCAATGGTTATACGA
GCACTAGGAGGAATTCTAGCTCCAATATATTTTGGGGCTCTGATTGATACAACGTGTATA
AAGTGGTCCACCAACAACTGTGGCACACGTGGGTCATGTAGGACATATAATTCCACATCA
TTTTCAAGGGTCTACTTGGGCTTGTCTTCAATGTTAAGAGTCTCATCACTTGTTTTATAT
ATTATATTAATTTATGCCATGAAGAAAAAATATCAAGAGAAAGATATCAATGCATCAGAA
AATGGAAGTGTCATGGATGAAGCAAACTTAGAATCCTTAAATAAAAATAAACATTTTGTC
CCTTCTGCTGGGGCAGATAGTGAAACACATTGTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="9">
      <id>BE0001042</id>
      <name>Solute carrier organic anion transporter family member 2B1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18357</ref-id>
            <pubmed-id>22541068</pubmed-id>
            <citation>Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O94956" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 2B1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.</specific-function>
        <gene-name>SLCO2B1</gene-name>
        <locus>11q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>50-69
89-109
116-140
186-215
235-255
274-298
367-388
409-432
437-460
565-587
597-622
656-673</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.39</theoretical-pi>
        <molecular-weight>76709.98</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10962</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLCO2B1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB026256</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5006263</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O94956</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO2B1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>KIAA0880</synonym>
          <synonym>OATP-B</synonym>
          <synonym>OATP-RP2</synonym>
          <synonym>OATP2B1</synonym>
          <synonym>OATPB</synonym>
          <synonym>OATPRP2</synonym>
          <synonym>Organic anion transporter B</synonym>
          <synonym>Organic anion transporter polypeptide-related protein 2</synonym>
          <synonym>SLC21A9</synonym>
          <synonym>Solute carrier family 21 member 9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037115|Solute carrier organic anion transporter family member 2B1
MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKLFVLCHSLLQL
AQLMISGYLKSSISTVEKRFGLSSQTSGLLASFNEVGNTALIVFVSYFGSRVHRPRMIGY
GAILVALAGLLMTLPHFISEPYRYDNTSPEDMPQDFKASLCLPTTSAPASAPSNGNCSSY
TETQHLSVVGIMFVAQTLLGVGGVPIQPFGISYIDDFAHNSNSPLYLGILFAVTMMGPGL
AFGLGSLMLRLYVDINQMPEGGISLTIKDPRWVGAWWLGFLIAAGAVALAAIPYFFFPKE
MPKEKRELQFRRKVLAVTDSPARKGKDSPSKQSPGESTKKQDGLVQIAPNLTVIQFIKVF
PRVLLQTLRHPIFLLVVLSQVCLSSMAAGMAIFLPKFLERQFSITASYANLLIGCLSFPS
VIVGIVVGGVLVKRLHLGPVGCGALCLLGMLLCLFFSLPLFFIGCSSHQIAGITHQTSAH
PGLELSPSCMEACSCPLDGFNPVCDPSTRVEYITPCHAGCSSWVVQDALDNSQVFYTNCS
CVVEGNPVLAGSCDSTCSHLVVPFLLLVSLGSALACLTHTPSFMLILRGVKKEDKTLAVG
IQFMFLRILAWMPSPVIHGSAIDTTCVHWALSCGRRAVCRYYNNDLLRNRFIGLQFFFKT
GSVICFALVLAVLRQQDKEARTKESRSSPAVEQQLLVSGPGKKPEDSRV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010728|Solute carrier organic anion transporter family member 2B1 (SLCO2B1)
ATGGGCACAGAAAACACACCTGGAGGCAAAGCCAGCCCAGACCCTCAGGACGTGCGGCCA
AGTGTGTTCCATAACATCAAGCTGTTCGTTCTGTGCCACAGCCTGCTGCAGCTGGCGCAG
CTCATGATCTCCGGCTACCTAAAGAGCTCCATCTCCACAGTGGAGAAGCGCTTCGGCCTC
TCCAGCCAGACGTCGGGGCTGCTGGCCTCCTTCAACGAGGTGGGGAACACAGCCTTGATT
GTGTTTGTGAGCTATTTTGGCAGCCGGGTGCACCGACCCCGAATGATTGGCTATGGGGCT
ATCCTTGTGGCCCTGGCGGGCCTGCTCATGACTCTCCCGCACTTCATCTCGGAGCCATAC
CGCTACGACAACACCAGCCCTGAGGATATGCCACAGGACTTCAAGGCTTCCCTGTGCCTG
CCCACAACCTCGGCCCCAGCCTCGGCCCCCTCCAATGGCAACTGCTCAAGCTACACAGAA
ACCCAGCATCTGAGTGTGGTGGGGATCATGTTCGTGGCACAGACCCTGCTGGGCGTGGGC
GGGGTGCCCATTCAGCCCTTTGGCATCTCCTACATCGATGACTTTGCCCACAACAGCAAC
TCGCCCCTCTACCTCGGGATCCTGTTTGCAGTGACCATGATGGGGCCAGGCCTGGCCTTT
GGGCTGGGCAGCCTCATGCTGCGCCTTTATGTGGACATTAACCAGATGCCAGAAGGTGGT
ATCAGCCTGACCATAAAGGACCCCCGATGGGTGGGTGCCTGGTGGCTGGGTTTCCTCATC
GCTGCCGGTGCAGTGGCCCTGGCTGCCATCCCCTACTTCTTCTTCCCCAAGGAAATGCCC
AAGGAAAAACGTGAGCTTCAGTTTCGGCGAAAGGTCTTAGCAGTCACAGACTCACCTGCC
AGGAAGGGCAAGGACTCTCCCTCTAAGCAGAGCCCTGGGGAGTCCACGAAGAAGCAGGAT
GGCCTAGTCCAGATTGCACCAAACCTGACTGTGATCCAGTTCATTAAAGTCTTCCCCAGG
GTGCTGCTGCAGACCCTACGCCACCCCATCTTCCTGCTGGTGGTCCTGTCCCAGGTATGC
TTGTCATCCATGGCTGCGGGCATGGCCACCTTCCTGCCCAAGTTCCTGGAGCGCCAGTTT
TCCATCACAGCCTCCTACGCCAACCTGCTCATCGGCTGCCTCTCCTTCCCTTCGGTCATC
GTGGGCATCGTGGTGGGTGGCGTCCTGGTCAAGCGGCTCCACCTGGGCCCTGTGGGATGC
GGTGCCCTTTGCCTGCTGGGGATGCTGCTGTGCCTCTTCTTCAGCCTGCCGCTCTTCTTT
ATCGGCTGCTCCAGCCACCAGATTGCGGGCATCACACACCAGACCAGTGCCCACCCTGGG
CTGGAGCTGTCTCCAAGCTGCATGGAGGCCTGCTCCTGCCCATTGGACGGCTTTAACCCT
GTCTGCGACCCCAGCACTCGTGTGGAATACATCACACCCTGCCACGCAGGCTGCTCAAGC
TGGGTGGTCCAGGATGCTCTGGACAACAGCCAGGTTTTCTACACCAACTGCAGCTGCGTG
GTGGAGGGCAACCCCGTGCTGGCAGGATCCTGCGACTCAACGTGCAGCCATCTGGTGGTG
CCCTTCCTGCTCCTGGTCAGCCTGGGCTCGGCCCTGGCCTGTCTCACCCACACACCCTCC
TTCATGCTCATCCTAAGAGGAGTGAAGAAAGAAGACAAGACTTTGGCTGTGGGCATCCAG
TTCATGTTCCTGAGGATTTTGGCCTGGATGCCCAGCCCCGTGATCCACGGCAGCGCCATC
GACACCACCTGTGTGCACTGGGCCCTGAGCTGTGGGCGTCGAGCTGTCTGTCGCTACTAC
AATAATGACCTGCTCCGAAACCGGTTCATCGGCCTCCAGTTCTTCTTCAAAACAGGTTCT
GTGATCTGCTTCGCCTTAGTTTTGGCTGTCCTGAGGCAGCAGGACAAAGAGGCAAGGACC
AAAGAGAGCAGATCCAGCCCTGCCGTAGAGCAGCAATTGCTAGTGTCGGGGCCAGGGAAG
AAGCCAGAGGATTCCCGAGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>